Safety study of BAY 3547926 for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (HCC) that cannot be removed by surgery or has spread
- A lab test on a sample of your tumor must show a certain protein (GPC3)
- Your cancer has not been helped by or cannot get standard treatments like surgery or chemo
- You are well enough to do everyday activities (ECOG score 0 or 1)
- You have at least one tumor that can be measured by a CT or MRI scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This study compares two treatment approaches for advanced liver cancer that has spread within the liver but not to other parts of the body. Both treatments combine chemotherapy delivered directly to the liver with immunotherapy drugs to help your immune system fight the cancer.
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
This trial tests new treatment plans for people with advanced liver cancer that has worsened after initial therapy. The goal is to find more effective, personalized options based on how your cancer responds.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.